LivingGLP1
Study S000379

Impact of Tirzepatide on Lorlatinib-Associated Weight Gain and Metabolic Derangements in Patients With Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov record

Registration

Registration
NCT07782359
Acronym
NSCLC
Study type
INTERVENTIONAL
Phase
PHASE1
Masking
NONE
Status
NOT_YET_RECRUITING
Enrollment
30
Start
2026-10
Primary completion
2030-06
Lead sponsor
University of Chicago
Conditions
Lung Cancer
Interventions
DRUG:Tirzepatide
Results posted
FALSE

Registered primary outcomes

  • Body weight changes [1 year post treatment start]
  • Lipid changes [1 year post treatment start]
  • Change in Cmax [1 year post treatment start]
  • Change in Tmax [1 year post treatment start]
  • Bioavailability [1 year post treatment start]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.